Glenmark opens manufacturing plant in Switzerland
The new plant is for the supply of clinical trial material.
New Delhi, June 4, 2014: Glenmark Pharmaceuticals has opened a new manufacturing facility in Switzerland for supply of clinical trial material.
The company said in a statement that Glenmark Pharmaceuticals S.A (GPSA), a wholly-owned subsidiary of the company has opened its new cGMP compliant monoclonal antibody manufacturing facility in La Chaux-de- Fonds, Switzerland. The company also said that the manufacturing facility will supplement Glenmark's existing in-house discovery and development capabilities and will supply material for clinical development.
It may be noted here that the focus for the biologics R&D centre is to develop novel biologic entities for the treatment of pain, oncologic, inflammatory and respiratory conditions.
The Glenmark biologics research centre has filed several patents since its inception around 10 years back.